OESOPHAGEAL SQUAMOUS CELL CARCINOMA STAGE I

This adverse event was reported 5 times

These drugs are most commonly taken by patients reporting OESOPHAGEAL SQUAMOUS CELL CARCINOMA STAGE I:

# Drug Count
0 INTERFERON BETA-1A 2
1 BARICITINIB 1
2 BEPOTASTINE BESILATE 1
3 CISPLATIN 1
4 FLUOROURACIL 1
5 FLUOROURACIL CREAM, 0.5% 1
6 LOSARTAN 1
7 LOSARTAN POTASSIUM 1
8 PACLITAXEL 1
9 PACLITAXEL (AIBUMIN-BOUND) 1
See all common drugs associated with OESOPHAGEAL SQUAMOUS CELL CARCINOMA STAGE I

OESOPHAGEAL SQUAMOUS CELL CARCINOMA STAGE I is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 BEPOTASTINE BESILATE 1 0.0016
1 BARICITINIB 1 0.0003
2 FLUOROURACIL CREAM, 0.5% 1 0.0000
3 FLUOROURACIL 1 0.0000
4 CISPLATIN 1 0.0000
5 LOSARTAN POTASSIUM 1 0.0000
6 INTERFERON BETA-1A 2 0.0000
7 PACLITAXEL 1 0.0000
8 LOSARTAN 1 0.0000
See all drugs enriched for association with OESOPHAGEAL SQUAMOUS CELL CARCINOMA STAGE I

These drug classes are most commonly taken by patients reporting OESOPHAGEAL SQUAMOUS CELL CARCINOMA STAGE I:

# Drug class Count
0 Interferon beta [EPC] 2
1 Janus Kinase Inhibitor [EPC] 1
2 Microtubule Inhibitor [EPC] 1
3 Nucleoside Metabolic Inhibitor [EPC] 1
4 Platinum-based Drug [EPC] 1
See all common drug classes associated with OESOPHAGEAL SQUAMOUS CELL CARCINOMA STAGE I

OESOPHAGEAL SQUAMOUS CELL CARCINOMA STAGE I is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Interferon beta [EPC] 2 0.0000
1 Janus Kinase Inhibitor [EPC] 1 0.0000
2 Microtubule Inhibitor [EPC] 1 0.0000
3 Platinum-based Drug [EPC] 1 0.0000
4 Nucleoside Metabolic Inhibitor [EPC] 1 0.0000
See all drug classes enriched for association with OESOPHAGEAL SQUAMOUS CELL CARCINOMA STAGE I